Specialty Pharmacy

Study finds that mitochondria of tumor cells are critical to survival and proliferation.

Five pivotal phase 3 trial ongoing for oral proteasome inhibitor.

Low dose methotrexate more likely to cause infectious adverse events than higher doses of the same drug.

Wait times for care negatively impacts patient health.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Pfizer executive discusses the present and future of biosimilars.

Research ongoing to target treatment-resistant gout.

Researchers evaluate why early trials of dasatinib did not give conclusive results.

Drug could be less expensive to produce and less harmful to healthy cells.

Research finds a potential route for targeted therapies to inhibit development and progression.

Includes evidence-based advice on the best use for next generation direct-acting antivirals.

The first generic version of Valeant's bexarotene (Targretin) is now available from Mylan.

Pazopanib shows promise in soft tissue sarcoma patients.

Stem cells have been found to target inflammation in osteoarthritis or rheumatoid arthritis.

Top stories of the week on Specialty Pharmacy Times from July 6 to July 10.

Less than 1% of healthy patients enrolled in early-stage clinical trials experience serious adverse events, half of which are unrelated to the drug or procedure studied, a new meta-analysis suggests.

Premature aging of the lung cells plays a factor in pathogenesis.

Lower inflammation scores found in patients with RA receiving statins.

Pharmacy was charged with overbilling hemophilia patients.

Charitable drug distributors are improving access to essential medications for low-income, uninsured patients in the United States.

Exchange plan spending on hepatitis C drugs increased 96% in the first quarter of 2015.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how specialty pharmacy has been affected by HIPAA laws.

Preliminary evidence suggests that the first-generation antihistamines chlorcyclizine and hydroxyzine may fight HCV infection for pennies a day.

Patients who received secukinumab sustained improvements over one year of treatment.

Discovery may lead to cost effective treatment options.

Review the clinical data behind the FDA's approval of the combination drug Orkambi (lumacaftor/ivacaftor) for select patients with cystic fibrosis.

Access is open to US adult patients who are refractory to the most common anti-myeloma drug classes.

Complete protection seen in half of non-human primates vaccinated against repeated challenges with simian immunodeficiency virus.